Perspective Therapeutics, Inc. CATX
Set alert
At close · Oct 30
After hours · Oct 30, 5:53 PM ET
- YTD
- -58.18%
- 1 year
- -56.44%
- Open
- 1.12
- Prev close
- 1.17
- Mkt cap
- 131.27M
- Vol
- 2.31M
- Avg vol
- 2.02M
- EPS
- -1.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.09
- High
- 1.15
- Forward P/E
- -2.91
- Beta
- 1.47
- Short ratio
- 4.69
- Inst. own
- 81.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.97
- 200-d avg
- 12.20
- 1y target
- 16.15
5D chart
Signals (56)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 4:00 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:10 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 29, 3:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 4 days ago |
| RSI: Overbought | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:10 AM | 4 days ago |
| RSI: Oversold | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:45 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:50 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
News
-
6 days ago benzinga.com
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
1 week ago marketbeat.com
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective Therapeutics NYSEAMERICAN: CATX presented updated clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2026, reporting tumor responses, an…
-
1 week ago benzinga.com
Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced systemic treatments
1 week ago globenewswire.com
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
SEATTLE, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
-
3 weeks ago benzinga.com
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle…
3 weeks ago globenewswire.com
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
3 weeks ago defenseworld.net
Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterated by BTIG Research in a research note issued on Wednesday, Benzinga reports. They currently have a…
-
3 weeks ago benzinga.com
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
3 weeks ago globenewswire.com
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
3 weeks ago defenseworld.net
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat…
-
1 month ago benzinga.com
Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
1 month ago globenewswire.com
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
1 month ago benzinga.com
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
1 month ago benzinga.com
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
1 month ago benzinga.com
This $3 Biotech Could Be Worth $11.45, Analyst Says
Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical cancer treatments, according to William Blair.
1 month ago benzinga.com
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
-
1 month ago benzinga.com
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.
-
1 month ago benzinga.com
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
-
1 month ago benzinga.com
Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
1 month ago globenewswire.com
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
1 month ago globenewswire.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026
SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
2 months ago seekingalpha.com
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans
Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for…
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
-
2 months ago benzinga.com
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
2 months ago defenseworld.net
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX
Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with…
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
-
2 months ago benzinga.com
Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K Estimate
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 26.67 percent increase over losses…
2 months ago zacks.com
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
3 months ago zacks.com
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
3 months ago defenseworld.net
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the…
3 months ago globenewswire.com
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced…
3 months ago zacks.com
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in…
3 months ago defenseworld.net
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX
Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and…
3 months ago defenseworld.net
ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX
ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 687.2% in the undefined quarter, according to the company in its most recent Form 13F filing…
-
3 months ago benzinga.com
Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors
The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).Orphan medicinal product designation by the EC may provide…
-
3 months ago benzinga.com
Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
3 months ago benzinga.com
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.
-
5 months ago benzinga.com
Perspective Doses First Brain Tumor Patient in Radiopharmaceutical Study, Expands Cancer Drug Trial to Meningioma Patients
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the…
-
5 months ago benzinga.com
Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma Cohort
One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily…
-
7 months ago benzinga.com
Earnings Scheduled For March 16, 2026
Earnings Scheduled For March 16, 2026
8 months ago benzinga.com
This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
-
1 year ago benzinga.com
Earnings Scheduled For August 13, 2025
Earnings Scheduled For August 13, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session